Deciduous Therapeutics develops immune modulatory therapies that activate the body's natural immune mechanisms to eliminate senescent cells, which contribute to age-related diseases. By targeting these dysfunctional cells, the company aims to improve health span and mitigate the effects of inflammation and tissue remodeling associated with aging.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+2Founders
Product
Problem
Senescent cells, characterized by irreversible damage and inflammatory secretions, accumulate with age due to a failure in immune surveillance. These cells negatively impact their local environment, inducing inflammation and promoting extracellular matrix remodeling, which contributes to age-related diseases.
Solution
Deciduous Therapeutics develops novel immune-modulatory therapies designed to activate the body's endogenous immune mechanisms to selectively eliminate senescent cells. By targeting and removing these dysfunctional cells, the company aims to treat several classes of age-related diseases and improve overall health span. The company's molecules activate a critical endogenous immune surveillance mechanism, enabling the selective removal of senescent cells. This approach aims to ameliorate disease pathologies associated with aging.
Target Audience
The primary target audience includes individuals at risk of or affected by age-related diseases, as well as pharmaceutical companies and research institutions focused on developing therapies for aging and senescence.
Features
- Development of novel molecules that activate endogenous immune surveillance mechanisms.
- Selective targeting and elimination of senescent cells.
- Focus on treating age-related diseases by addressing the root cause of cellular senescence.
- Modulation of the immune system to recognize and clear dysfunctional cells.